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Abstract
Background: Observational studies, if conducted appropriately, play an important role in the decision-making
process providing invaluable information on effectiveness, patient-reported outcomes and costs in a real-world
environment. We conducted a systematic review of large-scale, prospective, cohort studies with the aim of (a)
summarising design characteristics, the interventions or aspects of the disease studied and the outcomes
measured and (b) investigating methodological quality.
Methods: We included prospective, cohort studies which included at least 100 adults with psoriasis or psoriatic
arthritis. Studies were identified through searches in electronic databases (Pubmed, Medline, Cochrane library,
Centre for Reviews and Dissemination). Information on study characteristics were extracted and tabulated and
quality assessment, using a checklist of 18 questions, was conducted.
Results: Thirty five papers covering 16 cohorts met the inclusion criteria. There were ten treatment-related studies,
only two of which provided a comparison between treatments, and six non-treatment studies which examined a
number of characteristics of the disease including mortality, morbidity, cost of illness and health-related quality of
life. All studies included a clinical outcome measure and 11 included patient-reported outcomes, however only two
studies reported information on patient utilities and two on costs. The quality of the assessed studies varied widely.
Studies did well on a number of quality assessment questions including having clear objectives, documenting
selection criteria, providing a representative sample, defining interventions/characteristics under study, defining and
using appropriate outcomes, describing results clearly and using appropriate statistical tests. The quality assessment
criteria least adhered to involved questions regarding sample size calculations, describing potential selection bias,
defining and adjusting for confounders and losses to follow-up, and defining and describing a comparison group.
Conclusion: The review highlights the need for well designed prospective observational studies on the
effectiveness, patient-reported outcomes and economic impact of treatment regimes for patients with psoriasis
and psoriatic arthritis in a real-world environment.
Background
Psoriasis is a chronic, non-contagious skin disease that
commonly leads to appearance of red scaly patches on
the skin. Psoriatic arthritis is a chronic, disabling inflam-
matory disease, associated with psoriasis. In psoriatic
arthritis patients, the immune system attacks its own
joints thus leading to joint destruction associated with
cartilage deterioration, bone damage and joint fusion.
Prevalence of the disease is around 2-3% of the world
population. It causes considerable morbidity, signifi-
cantly affecting the quality of life of those suffering from
the disease [1-5]. Psoriasis is linked with psychological
distress [6], depression [7,8], pain and physical disability
[9]. In addition it carries significant economic implica-
tions, due to direct costs of management and costs asso-
ciated with productivity losses [10-13]. Furthermore,
there is some evidence to suggest that psoriasis and
psoriatic arthritis may be associated with the develop-
ment of heart disease, cancer and infections leading to
premature death [14-17].
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There are a number of systemic treatments for psoria-
sis and psoriatic arthritis which have been examined in
numerous randomised controlled trials (RCTs) [18,19].
However, while RCTs are considered the gold standard
for evidence-based decision making, it has been argued
that observational studies have an important role in the
measurement of effectiveness, longer-term outcomes,
rare adverse events, and other outcomes requiring a
more naturalistic study environment, for example the
measurement of resource use and health-related quality
of life (HRQOL) [20,21]. RCTs are generally designed to
test efficacy and safety. Although efficacy and effective-
ness both address the issue of whether a particular
intervention works or not, efficacy assesses whether an
intervention works under optimal circumstances,
whereas effectiveness assesses whether an intervention
works in usual care. Effectiveness is meant to be a more
pragmatic measure that addresses the utility of a drug as
it is actually employed in practice, therefore to measure
effectiveness it is necessary to mirror a real-world envir-
onment as much as possible. RCTs often use narrow
inclusion criteria and exclude patients with specific co-
morbidities. In addition, sample sizes can be restricted
and follow-up periods short. Such design characteristics
mean that RCTs often have low external validity (how
results can be generalised to the wider population)
which limits their use in guiding treatment in routine
clinical practice.
An observational study, by definition, is a study in which
the investigators do not seek to intervene, only observe
the course of events. Changes or differences in one charac-
teristic (e.g. whether or not people received systemic treat-
ment) are studied in relation to changes or differences in
other characteristics (e.g. whether or not HRQOL
improved), without action by the investigator. Such studies
have high external validity but lower internal validity than
RCTs. Results are more generalisable, but it is more diffi-
cult to attribute differences in outcomes between compari-
son groups to the particular intervention or characteristic
under observation because of potential differences in base-
line patient characteristics or because of losses to follow-
up. It is important therefore for observational studies to be
well designed and constructed and employ techniques to
minimise the susceptibility of bias. Of the three types of
observational study (cohort, cross-sectional and case-con-
trol), the cohort study stands at the top of the hierarchy of
clinical observational evidence as it measures events in
temporal sequence and can thereby more easily distin-
guish cause from effect. It is the most appropriate method
to measure incidence of specific events, the natural history
of the disease, changes in health states and use of health-
care resources.
Observational studies can play an important role in
the decision-making process. The National Institute of
Clinical Excellence stresses that decision-makers need to
assess and appraise all the available evidence regardless
of whether it has been derived from a RCT or an obser-
vational study. In the United States comparative effec-
tiveness research (i.e. the direct comparison of existing
health care interventions to determine which work best
for which patients and which pose the greatest benefits
and harms) assesses effectiveness in patients typical of
day to day clinical care and therefore the focus is on
‘real life’ studies rather than RCTs. Such comparative
effectiveness research is being employed by the govern-
ment to improve the quality of health care whilst redu-
cing the rising costs. Both approaches have their
strengths and weaknesses and it is important for deci-
sion-makers to understand these when using the evi-
dence to inform them of the appropriate use of
interventions in routine clinical practice [22]. Response
to treatment in patients with psoriasis is unpredictable
and often patients become resistant. This leads to indivi-
dualised treatment regimes. The restrictive nature of
RCTs would not necessarily highlight the outcomes that
would be seen usual clinical practice where patients are
often exposed to a number of different treatment
regimes before response is achieved. Also as some of the
treatments are associated with potentially serious side-
effects, longer-term observational studies can provide
important additional information to a variety of stake-
holders including clinicians, payers, providers and
patients when weighing up the risks and benefits of
treatment.
We carried out a comprehensive review of large-scale,
prospective, cohort studies conducted on patients with
psoriasis and psoriatic arthritis. Our primary aim was to
(a) summarise the design characteristics, the interven-
tions or aspects of the disease studied and the outcomes
measured and (b) investigate the methodological quality
of included studies.
Methods
We included prospective, cohort studies which included
at least 100 adults with psoriasis or psoriatic arthritis.
We included ‘treatment’ studies that focused on a parti-
cular intervention, drug or group of drugs with any
comparison and ‘non-treatment’ studies that assessed
the impact on psoriasis or psoriatic arthritis on morbid-
ity, mortality, resource use or HRQOL. We excluded all
studies with an experimental element to them (RCTs,
open-label studies and open-label extensions). We also
excluded retrospective studies, cross-sectional studies,
studies where patient’s age was less than 18 years old
and unpublished studies. We employed a cut-off of 100
patients to define large scale because (a) a recent health
technology assessment of the management of psoriasis
employed this cut-off for observational studies [23] and
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(b) other studies have used this as a cut-off to define
large scale studies [24].
A systematic electronic literature search was conducted
to identify published reports using the following data-
bases; PUBMED (1965 to 2009), MEDLINE (1989 to
2009), Cochrane Library (which includes Cochrane
reviews, other reviews, clinical trials, methods studies,
technology assessments and economic evaluations), the
Centre for Reviews and Dissemination Database (which
includes the Database of Abstracts of Reviews of Effects,
NHS Economic Evaluation Database, Health Technology
Assessment Database) and one internet search engine
(google). Additionally the following databases were
reviewed to search for ongoing and planned studies;
TRIP Turning Research into Practice database, National
research register, ClinicalTrials.gov, Current Controlled
Trials, Early Warning System and Salford database of
psoriasis trials. Search terms combined disease terms
(psoriasis and psoriatic arthritis) with study types (cohort,
epidemiologic, follow-up, longitudinal, prospective, regis-
tries, Phase IV, observational). Studies were restricted to
those in humans and in the English language. For exam-
ple the search string used in PUBMED and MEDLINE
was ("Psoriasis/drug therapy"[Mesh] OR “Psoriasis/eco-
nomics"[Mesh] OR “Psoriasis/epidemiology"[Mesh] OR
“Psoriasis/prevention and control"[Mesh] OR “Psoriasis/
statistics and numerical data"[Mesh] OR “Psoriasis/thera-
py"[Mesh] OR “Arthritis, Psoriatic/drug therapy"[Mesh]
OR “Arthritis, Psoriatic/epidemiology"[Mesh] OR
“Arthritis, Psoriatic/prevention and control"[Mesh] OR
“Arthritis, Psoriatic/therapy"[Mesh]) AND ("Cohort Stu-
dies"[Mesh] OR “Epidemiologic Studies"[Mesh] OR “Fol-
low-Up Studies"[Mesh] OR “Longitudinal Studies"[Mesh]
OR “Prospective Studies"[Mesh] OR “Registries"[Mesh]
OR “Clinical Trials, Phase IV as Topic"[Mesh] OR “open
label"[All Fields] OR “observational”).
Titles and abstracts from the initial search were
reviewed to identify relevant papers. A full paper review
was then conducted on all those that met the general
inclusion criteria. Reference lists of relevant studies were
also hand searched to identify additional data. Contact
with authors was not deemed necessary for the ques-
tions posed in this systematic review. Of those papers
thought to be eligible, data on study characteristics were
extracted and tabulated. Information collected included
study design, objectives, patients, outcome measures,
results, statistical methods and funding sources.
A quality assessment was conducted on all included
studies. Although there are now guidelines on the
reporting of observational studies (Strengthening the
Reporting of Observational Epidemiological studies -
STROBE) [25] which guide the author how to present
their data, there are no consensus guidelines on quality
assessment of such studies. A multitude of tools exist
that claim to assess the validity of published observa-
tional studies [26]. We devised our own quality assess-
ment tool based on a number of papers including the
Downs and Black score system [27], the STROBE state-
ment [25] and a recent systematic review of measures
for assessing quality and susceptibility to bias in obser-
vational studies [26]. Each study was assessed against a
list of 18 questions outlined in table 1. All results were
summarised descriptively.
Results
A total of 1018 papers were identified from the combi-
nation of searches (Figure 1). Fifty-eight papers were
obtained for full paper review, of which 35 papers were
identified as eligible for inclusion into the review. Rea-
sons for exclusion included study design was experimen-
tal [28-43], sample size too small [44], the patients
included were originally from a clinical trial [3,45-51],
the study involved retrospective identification of patients
[14,15,52-54] and the study was just a description of
medications used with no attempt to assess outcomes
[55].
The thirty-five papers relate to 16 observational stu-
dies, of which five were registry studies (Table 2). Nine
were studies of psoriasis, six of psoriatic arthritis and
one combined both conditions. Of the ten treatment-
related observational studies only four evaluated biologi-
cal agents; with the other six examining traditional
therapies. Only two provided a comparison between two
treatments. Of the six non-treatment related observa-
tional studies a number of characteristics of psoriasis
and psoriatic arthritis were examined including mortal-
ity, morbidity, disease progression, cost of illness and
aspects of HRQOL. Follow-up periods ranged from 3
months to 26 years.
Table 3 outlines the clinical, patient-reported and cost
measurements described in each of the studies. The
main clinical outcome measure used in the psoriasis stu-
dies was the Psoriasis area and severity index (PASI),
with some studies using the self-administered version of
this measurement (SPASI). In the psoriatic arthritis stu-
dies the most common clinical measurements were
those relating to tender and swollen joint counts with
three of the studies using the disease activity score-28
(DAS) based on 28 tender and swollen joint counts. Ele-
ven studies incorporated patient-reported outcomes into
their analysis. The most common patient-reported out-
come was the health assessment questionnaire (HAS)
used in six studies, followed by the SF-36 used in five
studies. One study used a questionnaire on experiences
with skin complaints (QES) and one used the dermatol-
ogy life quality index (DLQI). Only two studies assessed
health utilities either using the EQ-5D or the SF-6D and
again only two studies reported information on costs.
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Overall the quality of the included cohort studies,
measured against a checklist of 18 questions, ranged
from 41% to 89% (taking into account the questions
that were not applicable for certain studies) (Table 4).
Figure 2 outlines the proportion of the 16 studies that
met each of the quality assessment criteria. The studies
in general did well on a number of quality assessment
questions including having clear objectives, documenting
selection criteria, providing a representative sample,
defining interventions/characteristics under study, defin-
ing and using appropriate outcomes, describing results
clearly and using appropriate statistical tests (where
described). However, the studies fell short on a number
of other quality assessment criteria. Only one study
reported a sample size calculation or reported whether
the sample size was sufficient for the study objectives.
Only a third described potential selection bias. Around
50% described potential confounders and only a third
adjusted for these potential confounders. Also, although
over 60% reported losses to follow-up, less than a third
made any adjustments for them in the analysis. Only
around 60% of all studies identified and described a
comparison group. Overall the proportion of studies
meeting each quality assessment criteria ranged from
10% (sample size calculation and sufficient power) to
100% (patient characteristics described, validity of out-
comes and results clearly described).
Discussion
Three important points can be concluded from this sys-
tematic review of large scale, prospective, observational
studies conducted in patients with psoriasis or psoriatic
arthritis. First, very few large-scale, prospective, observa-
tional studies have been conducted given the burden of
Table 1 Quality assessment tool
Item Question
Patients/selection bias 1) Is the hypothesis/aim/objective of the study clearly described?
2) Are the characteristics of the patients included in the study clearly described?
3) Is the patient sample representative of patients treated in routine clinical practice?
4) Is there information on possibility of selection bias present in study?
Interventions 5) Are the interventions of interest clearly described? Treatments should be clearly described. In non-treatment related
observational studies the characteristics under study should be clearly described.
Comparison 6) Was a comparison group identified and clearly defined?
Outcomes 7) Are the main outcomes to be measured clearly described in the Introduction or Methods section? If the main
outcomes are first mentioned in the Results section, the question should be answered no.
8) Were the main outcome measures used accurate (valid and reliable)? For studies where the outcome measures are
clearly described, the question should be answered yes. For studies which refer to other work or that demonstrates the
outcome measures are accurate, the question should be answered as yes.
9) Have all important adverse events that may be a consequence of the intervention been reported? This should be
answered yes if the study demonstrates that there was a comprehensive attempt to measure adverse events. (A list of
possible adverse events is provided).
Reported findings/statistical
analysis
10) Are the main findings of the study clearly described? Simple outcome data (including denominators and
numerators) should be reported for all major findings so that the reader can check the major analyses and conclusions.
(This question does not cover statistical tests which are considered below)
11) Does the study provide estimates of the random variability in the data for the main outcomes? In non normally
distributed data the inter-quartile range of results should be reported. In normally distributed data the standard error,
standard deviation or confidence intervals should be reported. If the distribution of the data is not described, it must be
assumed that the estimates used were appropriate and the question should be answered yes.
12) Were the statistical tests used to assess the main outcomes appropriate? The statistical techniques used must be
appropriate to the data. For example nonparametric methods should be used for small sample sizes. Where little
statistical analysis has been undertaken but where there is no evidence of bias, the question should be answered yes. If
the distribution of the data (normal or not) is not described it must be assumed that the estimates used were
appropriate and the question should be answered yes.
Confounding 13) Are the distributions of principal confounders in each group of subjects to be compared clearly described? A list
of principal confounders is provided.
14) Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?
Losses to follow-up 15) Were losses of patients to follow-up reported?
16) Were losses of patients to follow-up taken into account? If the numbers of patients lost to follow-up are not
reported, the question should be answered as unable to determine. If the proportion lost to follow-up was too small to
affect the main findings, the question should be answered yes.
Power 17) Was a sample size calculation reported?
18) Did the study have sufficient power to detect a clinically important effect where the probability value for a
difference being due to chance is less than 5%?Sample sizes have been calculated to detect a difference of x% and y%.
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these diseases on society and the recent introduction of
biologic agents onto the market, with only two assessing
a drug versus drug comparison. Psoriasis is the most
prevalent autoimmune disease in the United States. It
affects 125 million people worldwide (2-3% of the total
population). Between 10 and 20% of people with psoria-
sis will develop psoriatic arthritis [56]. These conditions
cause significant morbidity and have been associated
with an increased risk of mortality compared to the gen-
eral population [17]. They significantly affect a patient’s
HRQOL and ability to carry out normal activities [4]
and the cost burden to society is substantial. In the Uni-
ted States psoriasis alone costs society $11.25 billion
annually, with work loss accounting for 40% of this cost
burden [57]. The recent introduction of biological thera-
pies represent an important addition to the approaches
used in the treatment of psoriasis and psoriatic arthritis,
however very few studies have assessed these agents in
real-life situations compared to the more traditional
treatments where many patient and provider factors, not
present in clinical trial environments, can impact on
effectiveness [58]. Also, in some countries these agents
are registered for use in specific target groups of
patients where evidence of efficacy and safety are not
provided by currently published clinical trials [58].
Finally, clinical trial data only provide short-term evi-
dence of efficacy and safety in a highly selected group of
patients. For all these reasons large scale, long-term
observational studies in real-life situations are needed to
guide appropriate clinical and policy decision making.
Second, given the importance of collecting health eco-
nomic data in a real world environment [20], very few
observational studies collected data on economic out-
comes or patient utilities. In the general hierarchy of
clinical evidence in healthcare decision making, RCT’s
remain the gold standard for evaluation. However, there
Studies identified in 
electronic search
(n=1018 )
Papers excluded on the basis 
of title and abstract review
(n=969) 
Papers identified for 
full paper review
(n=49) 
Total papers identified 
for full paper review
(n= 65) 
Papers excluded on the basis 
of title and abstract review
(n=30) 
Eligible papers
 (n=35) 
Papers identified from 
reference lists
(n=16)
Eligible studies
 (n=16) 
Figure 1 Flow diagram of included studies.
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are a number of situations where such studies may be
unnecessary, inappropriate, impossible or inadequate
[21]. The measurement of the effectiveness of a treat-
ment, the longer-term outcomes of treatment (clinical
and patient-reported), the true incidence of adverse
events, and resource use associated with treatment and
its side-effects are all situations where a RCT design is
inadequate. RCT’s often use patients, treatments and
healthcare professionals that are all atypical and in addi-
tion are often short-term. Resource use and patient utili-
ties observed in RCTs may not reflect that likely to be
observed in regular clinical practice, not least because
closer monitoring of patients in a trial may lead to
events being detected and treated sooner than would
otherwise be the case. This higher level of care may
result in a small number of patients not experiencing
Table 2 Characteristics of Included Studies
Primary reference, Study, Country (secondary
references)
Objectives Design Sample
size
Patient
population
Follow-up
Treatment-related observational studies
Driessen 2008 [68], Radboud University Registry, The
Netherlands (Driessen 2009 [69])
Efficacy and tolerability of etenercept and
efalizumab
Registry 118 Psoriasis 24 weeks
Fortune 2003 [6], PUVA Study, UK and Ireland Role of psychological distress on PUVA
treatment outcomes
Cohort 112 Plaque
psoriasis
(chronic)
2 years
Lecha 2005 [70], Spanish tacalcitol ointment study Efficacy and tolerability of tacalcitol Cohort 556 Psoriasis
(moderate)
2 months
Naldi 2008 [71], Psocare, Italy Effect of BMI on clinical response to
systemic treatment
Cohort 2368 Plaque
psoriasis
3 years
Paul 2003 [72] Cyclosporine study, Europe and Canada Incidence of malignancies in cyclosporine
treated patients
Cohort 1252 psoriasis -
severe
5 years
Wahl 2005 [73], Climate therapy study, Norway Effectiveness of climate therapy Cohort 286 Psoriasis 8 months
Heiberg 2008 [74], Norwegian register of disease
modifying anti-rheumatic drugs, (Heiberg 2007 [75])
Comparative effectiveness of TNF
inhibitors vs. methotrexate monotherapy
Registry 526 Psoriatic
arthritis
1 year
Kristensen 2008 [76], South Swedish Arthritis Treatment
Group register, (Gulfe 2009 [77], Geborek 2002 [78],
Kristensen 2006 [79])
Efficacy, utility and tolerability of TNF-
inhibitors (etanercept, infliximab,
adalimumab)
Registry 261 Psoriatic
arthritis
7 years
Sparado 1997 [80], Cyclosporin Study, Italy Probability of continuing to take
cyclosporine vs. other DMARDS
Cohort 172 Psoriatic
arthritis
10 years
Saad 2009 [81], British Society for Rheumatology
Biologics Register, (Harrison 2009 [82], Silman 2003 [83])
Effectiveness and tolerability of TNF-
inhibitors (etanercept, infliximab,
adalimumab)
Registry 566 RA, psoriasis,
psoriatic
arthritis
1 year
Non-treatment related observational studies
Carrascosa 2006 [84], EPIDERMA cost of illness, Spain Direct and indirect cost; relationship
between cost and severity
Cohort 797 Psoriasis 1 year
Colombo 2008 [11], Cost of illness, Italy Direct and indirect cost; HRQOL;
relationship between cost, HRQOL and
severity
Cohort 150 Moderate to
severe
plaque
psoriasis
3 months
Schmid-ott 2005 [85], Bad Bentheim Rehabilitation
Hospital, Germany
Relationship between the degree of
stigmatisation and gender, skin symptoms,
PASI and SPASI
Cohort 166 Psoriasis 1 year
Ali 2007 [86], Husted 2007 [2], Gladman 2009 [16],
Rohekar 2008 [87], Toronto PsA clinic, Canada,
(Chandran 2007 [88], Gladman 1995 [89], Gladman 1998
[90], Gladman 1999 [91], Gladman 2001 [92], Husted
2005 [93], Wong 1997 [94])
(1) Mortality associated with PsA; (2)
relationship between physical functioning,
disease activity and joint damage; (3) CVD
associated with PsA; (4) malignancies
associated with PsA
Cohort 382 to
680
Psoriatic
arthritis
26 years
Kane 2003 [95], St. Vincent’s University study, Ireland,
(Kane 2003a [96])
Clinical presentation, outcome and
prognosis of early PsA
Cohort 129 Early psoriatic
arthritis
2 years
Lindqvist 2008 [97], SwePsA registry, Sweden, (Svensson
2002 [98])
Factors associated with disease
progression; outcome of treated and non-
treated groups, comparison of outcomes
with RA patients
Registry 135 Early psoriatic
arthritis
2 years
PUVA, Psoralen Ultra-Violet A. TNF, Tumor Necrosis Factor. DMARD, disease-modifying anti-rheumatic drug. RA, rheumatoid arthritis. HRQOL, health-related quality
of life.
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high cost events that would be seen in everyday practice.
In economic terms this is important since economic
data is often highly skewed. The removal of a few obser-
vations with very high costs can have a large effect on
overall health economic results. Also, RCTs are often
conducted in specialist centres. The recorded resource
consumption seen in the trial will therefore reflect the
practice policies of this particular health care setting
which may be very different to usual clinical practice. It
is in such situations that observational cohort studies
would provide more appropriate and informative health
economic information if conducted and analysed
rigorously.
Third, of those studies included in this review overall
quality assessment was in general satisfactory, however
the majority of studies failed to take into account and
adjust for potential biases caused by lack of randomisa-
tion. Studies scored poorly on describing potential selec-
tion biases, identifying a comparison group, adjusting
for confounders and losses to follow-up and providing
adequate sample size calculations. The key question
posed in cohort studies is the comparison of outcomes
between two groups of patients (e.g. those responding to
treatment vs. those not responding to treatment). Just
over 60% of the studies in this review actually defined a
comparison group, be it the general population or a
more restricted internal or external population. For
those studies not providing a comparison it is almost
impossible to assess whether the results occurred by
chance. Of those reporting a comparison group most
Table 3 Clinical, patient-reported and cost measurements reported in included studies
Study (first
author*)
Measurements
Clinical Patient-reported Cost
Treatment-related observational studies
Driessen 2008
[68]
PASI - -
Fortune 2003
[6]
Time taken to achieve clearance of psoriasis Psychological distress, alcohol intake,
HADS
-
Lecha 2005
[70]
psoriasis severity and area, global efficacy and tolerability Patients’ satisfaction [tools not
described].
-
Naldi 2008
[71]
PASI, BMI - -
Paul 2003
[72]
Malignancies - -
Wahl 2005
[73]
SPASI SF-36, one item on QOL and one
assessment of self-acceptance
-
Heiberg 2008
[74]
DAS-28 HAQ; SF-36; SF-6D (utility) -
Kristensen
2008 [76]
DAS-28, erythrocyte sedimentation rate and C-reactive protein EQ-5D (utility) HAQ, VAS-pain, VAS-
global, global evaluation
-
Sparado 1997
[80]
Type of therapy; drug continuation; Number of painful and swollen joints;
remission
- -
Saad 2009
[81]
Drug persistence; DAS-28 HAQ adapted for UK use and SF-36 -
Non-treatment related observational studies
Carrascosa
2006 [84]
PASI Direct,
indirect
Colombo
2008 [11]
PASI SF-36, DLQI Direct,
indirect
Schmid-ott
2005 [85]
PASI, SPASI QES -
Husted 2007
[2]
Mortality; PASI; Duration of morning stiffness, and total numbers of actively
inflamed joints; incidence of CVD; malignancies
HAQ -
Kane 2003
[95]
PASI, Ritchie Articular Index, EULAR swollen joint count, joint stiffness on
waking.
HAQ -
Lindqvist
2008 [97]
66/68 joint counts, PASI, physician’s global assessment of joint disease activity,
and subclassification; remission
VAS, HAQ, SF-36 -
*Primary paper for the study or the most recent analysis of the cohort.
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studies reported potential selection bias however only
half accounted for confounders and only a third
accounted for losses to follow-up. In those studies not
addressing these issues of potential bias, results are
likely to have very low internal validity. Adjusting for
the potential bias caused by lack of randomisation is cri-
tical to the validity of cohort studies [59-61].
When interpreting the results of this systematic review
it is important to note three issues. First, it is difficult to
systematically search for observational studies as search
Table 4 Quality assessment of included studies
First author* 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Sum
Treatment-related observational studies
Driessen 2008 [66] 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 0 0 0 13
Fortune 2003 [6] 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 16
Lecha 2005 [68] 1 1 1 0 1 0 1 1 1 1 1 1 0 0 0 0 0 0 10
Naldi 2008 [69] 1 1 0 1 0 1 1 1 na 1 1 1 0 0 0 0 0 0 9
Paul 2003 [70] 1 1 1 0 1 1 1 1 0 1 1 1 1 0 0 0 0 0 11
Wahl 2005 [71] 1 1 1 0 0 0 1 1 na 1 1 0 0 0 0 0 0 0 7
Heiberg 2008 [72] 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 15
Kristensen 2008 [74] 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 0 0 14
Sparado 1997 [78] 1 1 1 0 0 1 1 1 1 1 0 1 0 0 1 1 0 0 11
Saad 2009 [79] 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 0 0 13
Non-treatment related observational studies
Carrascosa 2006 [82] 1 1 1 1 1 0 1 1 na 1 0 1 0 0 1 1 na na 11
Colombo 2008 [11] 1 1 1 0 1 1 1 1 na 1 0 1 0 0 1 1 na na 11
Schmid-ott 2005 [83] 0 1 1 1 1 0 1 1 na 1 0 1 0 0 1 1 na na 10
Husted 2007 [2] 1 1 1 0 1 1 1 1 na 1 1 1 1 1 1 0 na na 13
Kane 2003 [93] 1 1 1 0 1 0 1 1 na 1 1 1 0 0 1 0 na na 10
Lindqvist 2008 [95] 1 1 1 0 1 1 1 1 na 1 1 1 1 1 0 0 na na 12
*Primary paper for the study or the most recent analysis of the cohort. NA, not applicable.
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Sufficient power of sample size
Sample size calculation reported
Losses to follow-up adjusted for
Losses to follow-up reported
Confounders adjusted for
Confounders described
Statistical tests appropriate
Estimates of random variability described
Results described clearly
Adverse events reported
Validity of outcomes
Outcomes defined
Comparison group identified and defined
Interventions/characteristics defined
Potential selection bias described
Representative sample
Patient characteristics described
Clear objectives
Figure 2 Proportion (%) of studies meeting each of the quality assessment criteria.
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strategies that are both sensitive and specific do not
exist for the major electronic databases. To overcome
this problem we conducted a wide search and hand-
searched reference lists of key papers. Second, consensus
guidelines on the reporting of observational studies
(STROBE) have only recently been introduced [25],
therefore for many studies published prior to these
guidelines it is often difficult to identify if the paper is a
true observational study or not. Many studies stated
they were observational, but in actual fact incorporated
an experimental or ‘open-label’ element to them. Third,
the cut-off of 100 patients to define large scale may
have meant other important observational studies were
excluded. However, only one study was excluded on the
basis of sample size [44].
Large scale, prospective cohort studies are not the
only non-randomised method for capturing real world
health economic data. They are however, if conducted
rigorously one of the best approaches to use, especially
for non-rare outcomes over a relatively short period. A
number of cross-sectional and case-control studies
assessing cost, effectiveness and HRQOL have been con-
ducted in patients with psoriasis and psoriatic arthritis.
Cross-sectional studies are useful for assessing preva-
lence and describing specific characteristics of the dis-
ease, for example clinical and demographic
characteristics, patient and provider perceptions of effec-
tiveness, tolerability and compliance. However, unless
they incorporate a retrospective element into their
design, they are unable to distinguish between cause and
effect and therefore are inappropriate for the measure-
ment of effectiveness and health economic outcomes
associated with an intervention. Retrospective elements
to observational studies, for example retrospectively
identifying patients or retrospective data collection (as
in case control studies) introduces an additional level of
bias and are therefore often used for more descriptive
studies or hypothesis generation that can then be stu-
died in a prospective observational study.
Looking outside of true observational designs to stu-
dies which are non-randomised but incorporate an
experimental element to them, we find a number of
‘open-label’ trials, some aiming to assess longer-term
outcomes and others aiming to assess effectiveness in a
more naturalistic setting. These studies are not observa-
tional, although many claim to be. They are experimen-
tal in that patients have been selected for inclusion into
the trial and administered the trial treatment. Given that
these studies are not governed by any consensus guide-
lines on reporting or quality control, the potential for
risk of error or bias is high and the results should be
interpreted with caution. Included in these designs are
‘open-label’ extension studies. Patients represent a highly
select group that have not only been selected on the
basis of the original RCT, but are also those who have
completed the randomized element to the trial and
agreed to participate in the extension study. Such selec-
tion processes not only introduces significant bias, but
also lowers even further the generalisability of the
results to a wider population. In such studies the use of
inferential statistics to allow for the possibility of sam-
pling or random error to be the reason for the observed
difference is crucial. However, in most extension studies
assessing effectiveness in psoriasis or psoriatic arthritis
no such inferential statistics have been carried out
[62-64]. Also included are ‘open-label’ studies which
adopt a non-randomised approach from the start of the
study. Again these studies should be interpreted with
caution for two main reasons; first, treatment is experi-
mental and has therefore been selected by an investiga-
tor not independent from the study and second, the
patient will know which treatment they are being given.
Both actions will introduce inadvertent bias into the
outcome assessment. Furthermore it is essential that
such studies conform to the same rigorous methods
expected of true observational studies in that the bias
created from non-randomisation should be defined,
explored and adjusted for. Currently, apart from one
‘open-label’ phase IV study assessing health economic
outcomes which does account for confounding [34],
most of the others don’t [29,36,41].
Conclusion
There is a clear need for well designed, large-scale, pro-
spective observational studies in the field of psoriasis
and psoriatic arthritis particularly to assess the impact
of traditional and biological agents on economic and
patient-reported outcomes and the factors that influence
them, such as resistance and adherence, in a real world
environment. Several population-based registries are
currently being set up for both psoriasis and psoriatic
arthritis [58,65-67]. However, while such registries will
no doubt provide invaluable evidence on the long-term
risks and benefits of new and old treatments, they fall
short of providing adequate information on health eco-
nomic outcomes. The recommended core datasets for
registries include effectiveness measures [58,67],
HRQOL measures [67], but no patient utilities and
insufficient information with which to measure health
care resources or work productivity. Future observa-
tional studies measuring such outcomes would be a wel-
come addition to the scientific literature in this area and
would provide invaluable information to patients, clini-
cians and policy makers.
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